within Pharmacolibrary.Drugs.ATC.M;

model M03BA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 1.3333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M03BA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Febarbamate is a derivative of barbituric acid with muscle relaxant and sedative properties, formerly used as an anxiolytic and for the treatment of spasticity and muscle spasms. Its use is not approved or common in current clinical practice due to safety concerns and lack of comparative efficacy.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data are available for febarbamate in the scientific literature for any population, age, or route of administration. The following values are rough estimates based on typical small molecule barbiturates given orally in adults.</p><h4>References</h4><ol><li><p>Vachta, J, et al., &amp; Gold-Aubert, P (1983). Febarbamate: metabolism in man. <i>European journal of drug metabolism and pharmacokinetics</i> 8(3) 297–308. DOI:<a href=\"https://doi.org/10.1007/BF03188760\">10.1007/BF03188760</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6653620/\">https://pubmed.ncbi.nlm.nih.gov/6653620</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M03BA05;
